glp-1 vs glp-2 Medications for Weight Loss: Semaglutide Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 vs. GLP-2 vs. GLP-3:

Semaglutide 2.4mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection

Significance statement ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest

A new study based on real world data found a possible protective effect against multiple sclerosis for some of new weight loss medications.

Through its unique mechanism of action as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as well as its impressive results in clinical trials, tirzepatide has the potential to completely transform the current approach to treating obesity

SmartRx is one example of how that model comes to life

Discover timing, food restrictions, and absorption tips for better non-injection results.